clostridium%20difficile%20infection
CLOSTRIDIUM DIFFICILE INFECTION
Clostridium difficile infection is commonly associated with antibiotic treatment and is one of the most common nosocomial infections.
Symptoms usually start on days 4-9 of antibiotic treatment, but may also occur up to 8-10 weeks after discontinuation of antibiotics.
Discontinuation of antibiotics may be the only measure needed for patients with only mild diarrhea, no fever, no abdominal pain nor a high WBC count.
Cessation of antibiotics allows for reconstitution of the normal colonic microflora and markedly reduces risk of relapse.

Introduction

  • C difficile infection is commonly associated w/ antibiotic treatment & is one of the most common nosocomial infections

Signs and Symptoms

  • Symptoms usually start on days 4-9 of antibiotic treatment, but may also occur up to 8-10 weeks after discontinuation of antibiotics

Mild Disease

  • Watery diarrhea which is rarely bloody
  • Cramping abdominal pain, tenesmus
  • Anorexia, malaise
  • Slightly increased white blood cell (WBC) count

Moderate Disease

  • Fever
  • Dehydration
  • Nausea & vomiting
  • Abdominal tenderness
  • Leukemoid reaction

Severe Disease

  • Sepsis or shock
  • Acute abdomen which may be due to colonic perforation
  • Toxic megacolon, ascites, paralytic ileus
  • Hypoalbuminemia, increased WBC count & serum creatinine & lactate levels
  • Diarrhea may be of lesser severity in severe disease

Risk Factors

  • Antibiotic therapy
    • Antibiotics most commonly implicated are the cephalosporins, aminopenicillins & Clindamycin
    • Macrolides & other penicillins are less commonly involved
    • Prolonged antibiotic administration increases the risk of C difficile colitis, but even a brief exposure to a single antibiotic may cause disease
  • Intensive care unit (ICU) admission
  • Advanced age
  • Severe comorbid illnesses
  • Immunosuppressive therapy
  • Recent surgery
  • Use of a nasogastric tube
  • Use of antacids
  • Prolonged stay in the hospital
  • Residing in a nursing home
  • Sharing a hospital room w/ a C difficile-infected patient
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
6 days ago
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
4 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.